Chrysalis BioTherapeutics, Inc.
Chrysalis is pioneering the use of natural peptide regenerative drugs to restore vascular function and activate normal stem cell populations where they exist in the body. Our lead product TP508 has demonstrated potential for clinical benefit in human clinical trials and in preclinical studies for multiple clinical indications. Chrysalis has utilized non-dilutive funding to build a diverse pipeline with focus on mitigating effects of radiation. The TP508 Nuclear Countermeasure Program funded by NIH and BARDA is being developed under the FDA Animal Rule program with potential approval as early as 2025. It has become clear that ARDS is an endothelial vascular disease with vascular damage similar to that seen after radiation exposure. Chrysalis is developing TP508 to treat ARDS induced by Covid-19 and non-Covid related infection, inflammation, or traumatic injury.